References in periodicals archive ?
9] also studied the structure and emission spectrum of the europium cryptate containing 3,3-biisoquinoline-2,2-dioxide with the framework of the Sparkle/AM1 model and Judd--Ofelt theory.
This assay is based on the competition between the sample free cortisol and XL665 labelled cortisol for binding to an anticortisol europium cryptate labelled antibody.
We measured the concentrations of PAPP-A and hCG[beta] by use of a homogeneous random-access semi-automated assay, employing time-resolved amplified cryptate emission (TRACE) technology using the Kryptor instrument (Brahms AG).
Anion receptor molecules: synthesis of an octaaza-cryptand and structure of its fluoride cryptate.
Cisbio's cGMP assay kit is a homogeneous competitive immunoassay involving two HTRF congugates: cGMP coupled to XL665 and anti-cGMP monoclonal antibody labeled with Europium Cryptate.
We used time-resolved amplified cryptate emission (TRACE) technology in a Kryptor[R] autoanalyzer (BRAHMS) to measure plasma procalcitonin (PCT) concentrations in patients who developed an infection or AR on the day of the clinical diagnosis of these complications.
We set up a homogeneous sandwich fluoroimmunoassay using time-resolved amplified cryptate emission (TRACE) technology (29).
PCT concentrations were determined by the time-resolved amplified cryptate emission (TRACE) methodology on Kryptor (Brahms Diagnostic) by the same analyst, who followed the assay manufacturer's recommendations.
Time resolved amplification of cryptate emission: a versatile technology to trace biomolecular interactions [Review].
The 19-min homogeneous immunoassay technology (13), based on time-resolved amplified cryptate emission using chelates developed by Nobel Prize winner Jean-Marie Lehn, can be carried out in the same time that it takes a qualified sonographer to measure the fetal size (crown rump length) and nuchal translucency thickness and report a mini anomaly scan.
The research on intrinsically fluorescent, inert, and stable lanthanide chelate and cryptate labels has led to the development of novel homogeneous (21, 22) and heterogeneous assays (23, 24) that are expected to be introduced into routine clinical diagnostics.